22 related articles for article (PubMed ID: 38508329)
1. SMC2 knockdown inhibits malignant progression of lung adenocarcinoma by upregulating BTG2 expression.
He Y; Wang Y; Luo Z; Zhang X; Bai H; Wang J
Cell Signal; 2024 Aug; 120():111216. PubMed ID: 38729325
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics and experimental approach identify lipocalin 2 as a diagnostic and prognostic indicator for lung adenocarcinoma.
Li A; Zhang K; Zhou J; Li M; Fan M; Gao H; Ma R; Gao L; Chen M
Int J Biol Macromol; 2024 Jun; 272(Pt 2):132797. PubMed ID: 38848833
[TBL] [Abstract][Full Text] [Related]
3. Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway.
Liu M; Wu S; Wu H; Zhou Y; Zhang X; Zhu D; Jiang J
J Transl Med; 2024 May; 22(1):510. PubMed ID: 38802900
[TBL] [Abstract][Full Text] [Related]
4. GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma.
Zhou Z; Li Y; Chen S; Xie Z; Du Y; Liu Y; Shi Y; Lin X; Zeng X; Zhao H; Chen G
Cell Commun Signal; 2024 Jun; 22(1):303. PubMed ID: 38831321
[TBL] [Abstract][Full Text] [Related]
5. FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression.
Wu J; Wen T; Marzio A; Song D; Chen S; Yang C; Zhao F; Zhang B; Zhao G; Ferri A; Cheng H; Ma J; Ren H; Chen QY; Yang Y; Qin S
Cell Death Dis; 2024 Apr; 15(4):282. PubMed ID: 38643215
[TBL] [Abstract][Full Text] [Related]
6. DNAJC24 acts directly with PCNA and promotes malignant progression of LUAD by activating phosphorylation of AKT.
Liu D; Zuo R; Liu W; He Y; Wang Y; Yue P; Gong W; Cui J; Zhu F; Luo Y; Qi L; Guo Y; Chen L; Li G; Liu Z; Chen P; Guo H
FASEB J; 2024 May; 38(9):e23630. PubMed ID: 38713100
[TBL] [Abstract][Full Text] [Related]
7. PLEK2 activates the PI3K/AKT signaling pathway to drive lung adenocarcinoma progression by upregulating SPC25.
Zhang W; Yu L; Xu C; Tang T; Cao J; Chen L; Pang X; Ren W
Cell Biol Int; 2024 Jun; ():. PubMed ID: 38894536
[TBL] [Abstract][Full Text] [Related]
8. Lineage-specific intolerance to oncogenic drivers restricts histological transformation.
Gardner EE; Earlie EM; Li K; Thomas J; Hubisz MJ; Stein BD; Zhang C; Cantley LC; Laughney AM; Varmus H
Science; 2024 Feb; 383(6683):eadj1415. PubMed ID: 38330136
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic zinc finger protein ZNF687 accelerates lung adenocarcinoma cell proliferation and tumor progression by activating the PI3K/AKT signaling pathway.
Li M; Liu Z; Hou Z; Wang X; Shi H; Li Y; Xiao X; Tang Z; Yang J; Luo Y; Zhang M; Chen M
Thorac Cancer; 2023 May; 14(14):1223-1238. PubMed ID: 36944484
[TBL] [Abstract][Full Text] [Related]
10. TMEM158 functions as an oncogene and promotes lung adenocarcinoma progression through the PI3K/AKT pathway via interaction with TWIST1.
Xu T; Yin F; Shi K
Exp Cell Res; 2024 Apr; 437(1):114010. PubMed ID: 38508329
[TBL] [Abstract][Full Text] [Related]
11. TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway.
Fu Y; Yao N; Ding D; Zhang X; Liu H; Ma L; Shi W; Zhu C; Tang L
J Cell Physiol; 2020 Mar; 235(3):2761-2775. PubMed ID: 31531884
[TBL] [Abstract][Full Text] [Related]
12. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA (let-7b-5p)-targeted DARS2 regulates lung adenocarcinoma growth by PI3K/AKT signaling pathway.
Xu Y; Chen X
Oncol Res; 2024; 32(3):517-528. PubMed ID: 38361754
[TBL] [Abstract][Full Text] [Related]
14. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
